FDA has a less “tough guy approach” than HAS (see our post of June 10).
FDA did not withdrawn Actos® but published recommendations to limit its use.
FDA quoted the french Health Authority (HAS) in its drug safety communication about pioglitazone.
France supported the complete withdrawal of the drug by a study published by CNAMTS (salaried workers national health insurance scheme).
FDA support its restriction advise on a study by Takeda on the Kaiser Permanente Northern California (KPNC) health plan enrollees.
In the same time Germany recommends only not to start pioglitazone in news patients.